the CSF of patients

We have developed a novel real-time quaking-induced conversion RT-QuIC-based assay to detect alpha-synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson’s disease patients. This assay can detect alpha-synuclein aggregation in Dementia with Lewy bodies and Parkinson’s disease cerebrospinal fluid with sensitivities of 92% and 95%, respectively, and with an overall specificity of 100% when compared to Alzheimer and control cerebrospinal fluid. Patients with neuropathologically confirmed tauopathies (progressive supranuclear palsy; corticobasal degeneration) gave negative results. These results suggest that RT-QuiC analysis of cerebrospinal fluid is potentially useful for the early clinical assessment of patients with alpha-synucleinopathies.

[1]  U. Wüllner,et al.  Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein , 2015, Acta Neuropathologica Communications.

[2]  Clare E. Mackay,et al.  Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson’s disease , 2015, Brain : a journal of neurology.

[3]  Anne-Gaëlle Corbillé,et al.  La maladie de Parkinson est-elle une maladie à prion ? , 2015, Revue Neurologique.

[4]  J. Molinuevo,et al.  Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study , 2013, The Lancet Neurology.

[5]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[6]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[7]  K. Blennow,et al.  Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss? , 2009, Neuroscience Letters.

[8]  B. Mollenhauer,et al.  Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.

[9]  I. Ferrer,et al.  Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience , 2008, Dementia and Geriatric Cognitive Disorders.

[10]  E. Tolosa,et al.  Clinical overview of the synucleinopathies , 2003, Movement disorders : official journal of the Movement Disorder Society.

[11]  R Clarke,et al.  Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. , 1998, Archives of neurology.

[12]  M. Goedert,et al.  Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. , 1995, Genomics.

[13]  Y. Ben-Shlomo,et al.  The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. , 2014, Parkinsonism & Related Disorders.

[14]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[15]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.